Lv1
30 积分 2022-05-09 加入
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
8小时前
待确认
PD‐1‐Cis IL‐2R Agonism Determines the Predicted Pharmacological Dose Range for the Immunocytokine Eciskafusp Alfa (PD1‐IL2v)
20天前
已完结
Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
1个月前
已完结
Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?
2个月前
已完结
Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic T reg reduction and effector T cell activation
2个月前
已完结
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity
2个月前
已完结
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers
2个月前
已完结
ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy
3个月前
已关闭
N-803: a double-edged sword in haplo-NK therapy
3个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
5个月前
已完结
中国成年人生活方式和心血管代谢因素与甲基化年龄加速的相关性分析
3年前
已采纳
皮肤炎症性衰老与治疗策略
3年前
已采纳
皖公网安备34019202002308
